Nuo Therapeutics Inc

For the period ended Dec 31, 2023. Filed Apr 19, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Apr 19, 2024

AURXStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

	December 31,	December 31,
	2023	2022
Assets
Current assets
Cash and cash equivalents	$928,681	$2,051,208
Restricted cash	-	55,000
Accounts receivable, net	250,703	92,320
Inventory, net	209,589	240,005
Prepaid expenses and other current assets	174,471	196,378
Total current assets	1,563,444	2,634,911
Property and equipment, net	45,082	53,165
Operating lease right of use assets	269,354	359,284
Total assets	$1,877,880	$3,047,360
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable	$394,518	$397,703
Accrued expenses	188,622	123,275
Current portion of operating lease liabilities	91,387	79,453
Total current liabilities	674,527	600,431
Non-current portion of operating lease liabilities	164,205	255,592
Total liabilities	838,732	856,022
Commitments and contingencies (Note 8)
Stockholders' Equity
Common stock; $0.0001 par value; 100,000,000 shares authorized; 44,241,516 and 41,799,016 shares issued and outstanding at December 31, 2023 and 2022, respectively	4,424	4,180
Additional paid-in capital	30,970,965	28,951,963
Accumulated deficit	(29,936,241)	(26,764,805)
Total stockholders' equity	1,039,148	2,191,338
Total liabilities and stockholders' equity	$1,877,880	$3,047,360

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.